title: The efficacy of bromfenac ophthalmic solution 0.07% dosed once daily in achieving zero-to-trace anterior chamber cell severity following cataract surgery.
abstract: OBJECTIVE
  To evaluate the efficacy of bromfenac ophthalmic solution 0.07% dosed once daily in achieving zero-to-trace (0-5 cells) anterior chamber cells, following cataract surgery with posterior chamber intraocular lens implantation.
  
  
  METHODS
  The study designed employed two Phase III, double-masked, placebo-controlled, multicenter clinical trials of 440 subjects, randomized to either bromfenac ophthalmic solution 0.07% (n=222) or placebo (n=218). Subjects self-dosed once daily, beginning 1 day before undergoing cataract surgery with intraocular lens implantation (day -1) and again on the day of surgery (day 0) and for 14 days postoperatively. Follow-up was on days 1, 3, 8, and 15. The outcome measures included the percentage of subjects with zero-to-trace anterior chamber cells at each visit, as determined by the percentage of subjects with ≤5 anterior chamber cells, overall anterior chamber cell grades, and summed ocular inflammation score (SOIS) (combined anterior chamber cell and flare scores).
  
  
  RESULTS
  The proportion of subjects with zero-to-trace anterior chamber cells was significantly higher in the bromfenac 0.07% group compared with the placebo group as early as day 3 (P=0.0007), continued at day 8 (P<0.0001), and through day 15 (P<0.0001). At day 15, 80.2% of subjects in the bromfenac 0.07% group achieved zero-to-trace anterior chamber cells compared with 47.2% of subjects who did so in the placebo group. The overall anterior chamber cell scores were significantly lower in the bromfenac 0.07% group compared with the placebo group at days 3, 8, and 15 (P<0.0001 at each visit). The SOIS were also significantly lower in the bromfenac group compared with the placebo group at days 3, 8, and 15 (P<0.0001 at each visit).
  
  
  CONCLUSIONS
  Bromfenac ophthalmic solution 0.07%, dosed once daily was clinically effective in achieving zero-to-trace anterior chamber cell severity after cataract surgery and was superior to placebo in all anterior chamber cell severity and inflammation outcome measures.
authors.affiliation: Silverstein Eye Centers, Kansas City, MO, USA.
authors.forename: Steven M
authors.initials: SM
authors.lastname: Silverstein
authors.affiliation: Jacksoneye, Inc., Lake Villa, IL, USA.
authors.forename: Mitchell A
authors.initials: MA
authors.lastname: Jackson
authors.affiliation: Wolstan & Goldberg Eye Associates, Torrance, CA, USA.
authors.forename: Damien F
authors.initials: DF
authors.lastname: Goldberg
authors.affiliation: Bausch + Lomb, Irvine, CA, USA.
authors.forename: Mauricio
authors.initials: M
authors.lastname: Muñoz
keywords: anterior chamber inflammation; cells and flare; non-steroidal anti-inflammatory; ocular inflammation